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ABSTRACT 
GPCR allosteric modulators target at the allosteric, “allo- from the Greek meaning "other", 
binding pockets of G protein-coupled receptors (GPCRs) with indirect influence on the effects of 
an agonist or inverse agonist. Such modulators exhibit significant advantages compared to the 
corresponding orthosteric ligands, including better chemical tractability or physicochemical 
properties, improved selectivity, and reduced risk of over-sensitization towards their receptors. 
Metabotropic glutamate receptor 5 (mGlu5), a member of GPCRs class C family, is a promising 
therapeutic target for treating many central nervous system (CNS) diseases. The crystal structure 
of mGlu5 in the complex with the negative allosteric modulator (NAM) mavoglurant was recently 
reported, providing a fundamental model for the design of new allosteric modulators. However, 
new NAM drugs are still in critical need for therapeutic uses.  Computational fragment-based drug 
discovery (FBDD) represents apowerful scaffold-hopping and lead structure-optimization tool for 
drug design. In the present work, a set of integrated computational methodologies was first used, 
such as fragment library generation and retrosynthetic combinatorial analysis procedure (RECAP) 
for novel compound generation. Then, the new compounds generated were assessed by benchmark 
dataset verification, docking studies, and QSAR model simulation. Subsequently, the structurally 
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diverse compounds, with reported or unreported scaffolds, can be observed from the top 20 in 
silico design/synthesized compounds, which were predicted to be potential mGlu5 allosteric 
modulators. The in silico designed compounds with reported scaffolds may fill SAR holes in the 
known, patented series of mGlu5 modulators. And the generation of compounds without reported 
activities on mGluR indicates that our approach is doable for exploring and designing novel 
compounds. Our case study of designing allosteric modulators on mGlu5 demonstrated that the 
established computational fragment-based approach is a useful methodology for facilitating new 
compound design and synthesis in the future. 
 
Keywords: Allosteric modulator, Computational fragment-based drug discovery, Metabotropic 
glutamate receptor 5, GPCRs  
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1.0 INTRODUCTION 
 
1.1 ORTHOSTERIC AND ALLOSTERIC REGULATIONS OF GPCRS 
 
The human G protein-coupled receptors (GPCRs), which can also be described as 7-
transmembrane (TM) receptors account for more than 1% of human genome. The GPCR 
superfamily, comprised more than 800 receptors, can be further categorized into four different 
classes, class A, B, C, and F (Frizzled), according to their sequence homology.(1, 2) As essential 
receptors associated with a variety of physiological processes, including neurotransmission, 
immune defense, and cell growth, over 30% of currently marketed drugs are using GPCRs as their 
targets.(3, 4) 
 Each GPCR possesses an orthosteric binding pocket for its respective endogenous ligands. 
Compounds derived from nature sources or chemical synthesis binding to this pocket are termed 
orthosteric ligands.(5) Early drug development was focused on the orthosteric modulation and 
almost all of the FDA-approved compounds for therapeutic use target at the orthosteric binding 
sites of the receptors.(5, 6) However, the ligands coming out from this strategy have drawbacks 
including limited or poor selectivity, a lack of efficacy, and resistance or decreased efficacy upon 
chronic administration.(7-9) GPCRs can have allosteric binding sites, which have topological and 
functional distinctions from corresponding orthosteric binding sites. The existence of allosteric 
binding pockets allows additional interactions between ligands and receptors. And the 
benzodiazepine class of compounds is a prime example of successful allosteric modulators.(5, 10, 
11) As shown in Figure 1, the number of publications that include the concept of “allosteric 
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modulators” per year has been increased, and the trend continues. Notably, more than 450 papers 
were published in 2016, which illustrates the elevated interests of allosteric regulation.  
 
Figure 1. The number of publications each year including the concept of “allosteric modulator” 
The search of papers on SciFinder with the key words “allosteric modulator” from 2001 to 2016 
demonstrate a trend of increased publications.  
 
Across a receptor family, the allosteric pockets usually stand with less evolutionary 
pressure for conservation, and the corresponding allosteric ligands usually have  better selectivity. 
Meanwhile, allosteric ligands have a ceiling effect, which means their effects are saturable.(12, 
13) Usually, orthosteric ligands could be categorized into agonist, antagonist, partial agonist, and 
inverse agonist, according to the physiological responses they trigger (Figure 2A). Based on the 
modes of pharmacology, allosteric ligands can be categorized into positive allosteric modulators 
(PAMs), which enhance agonist-mediated receptor response, negative allosteric modulators 
(NAMs), which noncompetitively attenuate orthosteric activities, and silent allosteric modulators 
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(SAMs), which have no effect on responses triggered by orthosteric ligands but block the effects 
caused by PAMs and NAMs (Figure 2B).(5)  
 
 
Figure 2. Categorization of GPCRs’ orthosteric ligands and allosteric modulators 
A. The categorization of orthosteric ligands. An agonist is a ligand that could bind the receptor 
and fully activate the receptor to produce a biological response. A partial agonist is a ligand that 
could also bind the receptor, but only partially activate the receptor. An antagonist is a ligand that 
could bind and block the receptor and prevent the generation of biological response. An inverse 
agonist is a ligand that binds the same receptor as an agonist but triggers opposite biological 
response. B.  The categorization of allosteric modulators. Allosteric modulators occupy allosteric 
binding pocket. A positive allosteric modulator (PAM) could increase the affinity or efficacy of 
the orthosteric agonist. A negative allosteric modulator (NAM) could decrease the affinity or 
efficacy of the orthosteric ligand. A silent allosteric modulator could only occupy the binding 
pocket, but does not have any influence on orthosteric ligands. 
 
The clinical success of the benzodiazepines suggests that allosteric regulation is a 
promising therapeutic strategy.(14) Cinacalcet and Maraviroc are two famous examples of 
successful developments of allosteric modulators. Cinacalcet is a positive allosteric modulator for 
calcium-sensing receptor, and got approved by FDA in March 2004. Maraviroc is a negative 
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allosteric modulator for CCR5 used in the treatment of HIV infection to prevent the fusion of the 
virus and the T cells. The Maraviroc was approved by FDA in August 2007. Meanwhile, a new 
category of ligands, termed bitopic ligands, emerged. Bitopic ligands should target the orthosteric 
binding pocket and allosteric binding pocket simultaneously. Giving that orthosteric ligands 
usually have the high affinity towards the receptor, and allosteric ligands would have better 
selectivity, designing bitopic ligands has the potential to combine these advantages. Tahtaoui and 
his group synthesized a series derivatives for M1AChR antagonist in 2004. The receptor-ligand 
interactions were assessed, and the authors found that these analogs could have interactions with 
both the orthosteric binding site and the allosteric binding site of the receptor. Therefore, these 
derivatives behave as potential bitopic ligands. Table 1 shows the currently marketed drugs and 
compounds in clinical trials that function as allosteric or bitopic ligands. 
 
Table 1. Marketed or under clinical investigation allosteric and bitopic ligands 
No. Drug Structure Target 
Indication and 
Stages 
1 
Cinacalcet 
(PAM) 
 
CaSR 
FDA-approved for 
Hyperparathyroi-
dism 
2 
Maraviroc 
(NAM) 
 
CCR5 
FDA-approved for 
HIV 
3 
Imatinib 
(NAM) 
 
BCR/ 
ABL and 
KIT 
FDA-approved for 
chronic 
myelogenous 
leukemia 
4 
Reparixin 
(NAM) 
 
CXCR1/ 
CXCR2 
Phase II/III for 
reperfusion injury to 
lung/kidney 
transplantation 
5 
 
5 
MK2206 
(NAM) 
 
AKT1, 
AKT2, 
AKT3 
Phase II for acute 
lymphoblastic 
leukemia 
6 
AZD2423 
(NAM) 
 
CCR2  
Phase II for 
neuropathic pain 
7 
Norclozapine 
(PAM) 
 
ACM1 
Phase II 
Schizophrenia 
8 
Litronesib 
(NAM) 
 
KNSL1  
Phase II  
antineoplastic 
activity 
9 
 
ADX71149 
(PAM) 
 
mGluR2 
phase II for 
schizophrenia 
10 
AZD8529 
(PAM) 
 
mGluR3/2 
phase II for 
schizophrenia 
11 
STX107 
(NAM) 
-- mGluR5 
Phase III for Fragile 
X, Phase II for 
autism 
12 
AFQ056 
(NAM) 
 
mGluR5 
Phase II completed 
PD-LID, Fragile X 
13 
Dipraglurant 
(NAM) 
 
mGluR5 
Phase II PD-LID, 
Dystonia 
14 
RO 4917523 
(NAM) 
 
mGluR5 
Phase II for Fragile 
X, depression 
15 
Fenobam 
(NAM) 
 
mGluR5 
Phase II for Fragile 
X 
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16 
CDPPB 
(PAM) 
 
mGluR5 depression 
17 
AMN082 
(PAM) 
 
mGluR7 
Phase II for 
hypercholesterolemi
a 
18 
Alprazolam 
(PAM) 
 
GABAA anxiolytic 
19 
Bentazepam 
(PAM) 
 
GABAA anxiolytic 
20 
Bretazenil 
(PAM) 
 
GABAA 
anxiolytic,anticonvul
sant 
21 Midazolam 
 
GABAA 
hypnotic, 
anticonvulsant 
22 Oxazepam 
 
GABAA anxiolytic 
 
 
1.2 GLUTAMATE RECEPTORS 
 
Metabotropic glutamate receptor 5 (mGlu5) is a member of class C GPCRs, which mainly 
responds to glutamate, one of the major neurotransmitters.(15) Class C GPCRs include 
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metabotropic glutamate receptors, taste receptors, calcium-sensing receptors, GABAB and others. 
mGlu5 is a promising drug target for the treatment of diseases ranging from fragile X syndrome 
to depression and movement disorders.(16) mGlu5 negative allosteric modulators, which could 
attenuate orthosteric ligands mediated mGlu5 activation, are under clinical evaluation for the 
treatment of multiple diseases.(17, 18) Dr. Fiona H. Marshall and her group have reported the 
crystal structure of the transmembrane domain of human mGlu5 receptor, in the complex with the 
negative allosteric modulator mavoglurant (Figure 3).  
 
 
Figure 3. Crystalized structure of mGlu5 transmembrane domain in complex with mavoglurant 
A. View from the membrane side. B. Top view from the extracellular side.  
 
The structure shows that mavoglurant binds between helixes 2, 3, 5, 6, 7 and make 
interactions with Ser805, Ser809, and Asn747. Multiple research groups have focused on the 
allosteric regulation of mGlu5, for example, Andreas Ritzen' group and P. Jefferey Conn's group 
designed and synthesized a series of allosteric ligands for mGlu5.(19) With the availability of the 
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crystal structure a classical structure-based medicinal chemistry approach could be useful for the 
generation of corresponding allosteric modulators, state-of-the-art computational methods could 
also be powerful tools in generating new ideas in allosteric modulator design in this field.(20, 21) 
 
1.3 FRAGMENT-BASED DRUG DESIGN 
 
Fragment-based approaches for designing and generating lead compounds have proven quite 
fruitful in drug discovery. There are several ways that fragment-based approach could be applied 
to drug discovery: (1) binding sites and pharmacophores identification for receptor binding could 
be achieved with fragment screening techniques; (2) HTS libraries could be biased and the 
optimization of lead compounds could be guided with fragments screening hits; (3) leads with the 
potential to be optimized into drug-like compounds can be identified with fragment screening.(21-
25) Fragment binding can reveal hot spots on proteins, which could result in high-affinity receptor-
ligand interactions. The fragment-based approach is especially suitable for detecting the 
interaction spots among the protein-ligand binding, as fragments are capable of interacting with a 
certain region of the target protein. Once the identification of fragments inside the binding pocket 
is done, these fragments could be grown, linked or merged to develop the potential ligands (Figure 
4).(21)  
 
 
9 
 
 
 
Figure 4. Commonly used strategies for fragment-based drug design 
A. Growing. After identification of one suitable fragment inside the binding pocket, substitutions 
could be added to the identified fragment. The growing process would increase the lead likability 
of the original fragment to enhance the receptor-ligand interactions. B. Linking. Multiple 
fragments could be identified for one binding pocket simultaneously targeting at different regions. 
Linkers would be introduced to connect separated fragments to increase the lead likability, and to 
create a novel compound with potential affinity towards the pocket. C. Merging. A known lead 
could partially occupy the binding pocket. One or more fragment(s) could be identified to be 
suitable for the remaining space. One or more linker(s) could be introduced to connect the known 
lead and the fragment(s) to increase the strength of receptor-ligand interactions. 
 
A number of fragment based screening campaigns have successfully delivered clinical 
candidates.(26) Steven Howard and his group successfully applied fragment-based screening and 
fragments linking to discover novel thrombin inhibitors.(27) Philip D. Edwards and his group 
reported the novel cyclic amidine β-secretase with the fragment-based approach to generate lead 
compounds.(28) However, there are still several undesired drawbacks for this approach. The 
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defects of the experimental fragment-based method include time consuming, costly, and low 
affinity of hits.(21, 29, 30) Another complementary way to approach fragment-based drug 
discovery is the application of computational methods, which can offer several advantages: (1) 
computational methodologies can construct high quality and diversified fragment libraries with 
both time and cost efficiencies;(31, 32) (2) computational approaches can easily explore larger 
fragment databases; (3) optimization strategies for improving the drug-likeness of the hits with 
computational tools have efficiency and flexibility.(33) Recently,  a drug design effort, that 
involved virtual screening of a fragment library, binding confirmation by NMR, X-ray 
crystallography, and structure-based optimization of fragments, by a research group in 
AstraZeneca lead to the discovery of highly potent FXIa inhibitors(34). Another example is the 
development of inhibitors of cyclophilin A. Li’s group reported that amide fragments, which 
functions as the key linker, is one of the critical pharmacophores for CypA inhibitors.(35) Through 
computational FBDD approaches, acylurea was designed by fusing amide and urea to function as 
a new linker and contributed to the discovery of novel inhibitors.  Computational fragment-based 
drug design involves five major steps (Figure 5). First, the establishment of the diversified 
fragment library. Considering the advancement in computational power, a very large number of 
fragments can be screened in each experiment. This guarantees a good degree of fragment 
diversity and increases the statistical probability of finding suitable fragments for a given pocket. 
Second, virtual screening of the fragment library to find suitable fragments. Fragments are 
relatively small compounds, which would not likely give appealing binding energies or docking 
scores during the docking process. However, analysis of the potential receptor-ligand interactions, 
like H-bond or hydrophobic interactions, suitable fragments could be identified. Third, design the 
lead compounds based on identified fragments. As mentioned above, fragment growing, 
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fragments linking, and lead-fragments merging are strategies that can be used in this step. Fourth, 
the verification of generated novel leads with corresponding biological assays. Computational 
validation methods would be applied at the beginning to filter out false positives or false negatives. 
Corresponding biological assays would be followed to formally verify the effectiveness of these 
lead compounds. Fifth, NMR confirmation of binding. The last step mainly contributed to the 
mechanism understanding. After the growing, linking, or merging steps, fragments inside a 
compound may not recur at the identical places from the virtual screening. Confirming the binding 
mode of the compounds with NMR would reveal receptor-ligand interactions and provide insight 
for the mechanism of receptor activation or inhibition.  
 
 
 
Figure 5. Flowchart of computational fragment-based drug design 
Five major steps are considered. First, the establishment of diversified fragment library. Second, 
the virtual screening for the given target. Third, the fragments processing for the lead generation. 
Fourth, the hits validation with biological assays. Fifth, the confirmation of binding mode. 
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 In our research, we use a computational fragment-based approach to propose structures as 
potential novel allosteric modulators of mGlu5. We generated a fragment library from the reported 
GPCRs’ allosteric modulators on Allosteric Database (ASD v2.0).(36) Retrosynthetic 
combinatorial analysis procedure (RECAP) analysis and synthesis were used to generate the novel 
compounds. Molecular docking was applied to screen the hits for mGlu5 by docking the in silico 
synthesized compounds back to the pocket and predicted binding energy and docking scores. 
Computational methodologies, such as benchmark dataset verification, docking studies, QuaSAR 
model, etc. were utilized for further validation of our hits. 20 in silico synthesized compounds are 
predicted to be potential mGlu5 allosteric modulators with preferable binding energies and docking 
scores. Structure diversity among the in silico design could be observed. Series of compounds with 
reported allosteric activities on mGluR could be recurred. Our case study on designing allosteric 
modulators on mGlu5 suggested that this computational fragment-based approach is a useful 
methodology for facilitating the future compounds design processes. 
 
2.0 MATERIALS AND METHODS 
 
2.1 X-RAY STRUCTURES AND GPCR ALLOSTERIC MODULATORS 
 
Two x-ray structures of transmembrane domain of the human mGlu5 were used in this work. The 
first model (PDB entry: 4OO9; resolution, 2.6 Å; method, X-ray diffraction)(16) was in complex 
with the negative allosteric modulator, mavoglurant. The second model (PDB entry: 5CGD; 
resolution, 2.6 Å; method, X-ray diffraction)(37) was in complex with the negative allosteric 
modulator, HTL14242. The structures of mGlu5 were downloaded from the Protein Data Bank 
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(PDB). SYBYL-X 1.3(38) was used for the preparation of the crystal structures, including energy 
minimization and residues repair.(39) 
 Ligands downloaded from the Allosteric Database (ASD v2.0)(36) SYBYL-X 1.3 and 
PyMol (http://www.pymol.org) were used for molecular visualization, structural superimposition, 
and data analysis.(40) 
 
2.2 FRAGMENTS GENERATION AND IN SILICO SYNTHESIS 
 
The RECAP Analysis and RECAP Synthesis tools in the ChemAxon’s Fragmenter software 
(https://www.chemaxon.com) were used for the establishment of the fragment library from 
allosteric modulators in ASD and  the generation of in silico synthesized novel structures from 
processed, analyzed, and categorized fragments. The Molecule Filter was set to be Leadlike.(41) 
The Heavy Atoms were set to be 25 in average with 11 in standard deviation. The purpose of 
RECAP Analysis is to fragment compounds according to simple retrosynthetic analysis rules and 
gather statistics towards fragments products. The RECAP Synthesis could be applied to combine 
fragments products from RECAP Analysis randomly, in order to produce the novel chemical 
structures, which should be synthetically reasonable.(42, 43) . 
 
2.3 MOLECULAR DOCKING FOR THE STUDIES OF mGlu5-LIGAND 
INTERACTIONS 
 
We performed the molecular docking between crystal structure of mGlu5 and fragments in the 
fragment library using SYBYL-X 1.3. Surflex-Dock GeomX, the docking algorithm that 
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implemented in SYBYL, was applied to predict detailed receptor-ligands interaction. The Total 
Score was expressed as –log10(Kd).(44) In the docking simulations, the allosteric binding site was 
first defined to cover all residues within 4 Å of the NAM in the initial mGlu5-mavoglurant complex. 
The Kollman all-atom approach was used to calculate atomic charges for the protein(45) and the 
Gasteiger-Hückel approach for the ligand.(46) The movement of hydrogen atoms of the protein 
was allowed. Additional starting conformations per molecule were set to 10, and the angstroms to 
expand search grid was set to 6. Three independent runs were performed for our fragment library. 
 Molecular docking between the in silico synthesized compounds was done with SYBYL-
X 1.3 and AutoDock 4.0(47). The parameters stated above of SYBYL-X 1.3 were used in these 
docking experiment. For AutoDock, Lamarckian genetic algorithm (LGA),(48) was used in this 
study. The grid box contained the entire allosteric binding site of the mGlu5 and permitted 
translation and rotation of ligands. Numbers of points in Grid box for three dimensions were 24, 
24 and 22; spacing (angstrom) was 1.000. AutoGrid was used for calculating the energy map of 
each atom in the ligands. The receptor was set to be rigid. Genetic algorithm with default 
parameters was chosen for the search. A binding energy, which is constituted by intermolecular 
energy, internal energy, torsional energy and unbound extended energy, was reported for each run.  
 
2.4 GENERATION OF BENCHMARKING DATASET 
 
Enrichment of top hits was key metric for docking studies.(49) Once a docking screening could 
distinguish active compounds as top hits against a large number of decoys in the database, this 
docking screening is considered a success.(50) In order to distinguish the in silico synthesized 
compounds from decoys in the docking processes a benchmarking dataset is introduced. In the 
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spirit of the DUD(49) and DUD-E(51) reference data sets for validation studies, 50 decoys, which 
have similar physical properties but distinctive topological properties with the reported mGlu5 
NAM were generated through http://decoys.docking.org, using the reported protocols and 
parameters. 
 
2.5 QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP MODEL 
 
The correlation between the structures of molecules and their corresponding chemical or physical 
properties could be summarized and predicted with Quantitative structure-activity relationships 
(QSAR) techniques.(52) A QSAR model could be used to evaluate specific parameters that 
affecting some properties of the molecules or to estimate same properties for other molecules in 
the same series.(53) A QSAR model, dealing with the correlation between the LogKi value and 
theoretical descriptors for molecules, was developed using 66 analogs of 1,2-diphenylethyne 
mGlu5 NAMs with existing Ki values in ASD. Ki values underwent logarithmic transformation 
to get LogKi values. Kennard-Stones algorithm was used for determining the training and test sets. 
186 descriptors were added towards each compound. Four criteria, contingency coefficient, 
Cramer’s V, entropic uncertainty, and linear correlation were used to evaluate the contribution of 
each descriptor after the contingency analysis.(54-56) Partial least squares (PLS) regression 
method was used for building the model with selected descriptors. The model has been verified 
with the test set and used for the prediction of in silico synthesized compounds. 
 
3.0 RESULTS 
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3.1 STUDY DESIGN AND THE STRATEGIES FOR DESIGNING NOVEL 
COMPOUNDS 
 
In designing new leads we followed the workflow described in Figure 6. First, we constructed a 
diversified fragment library from GPCR allosteric modulators in ASD using RECAP Analysis. 
Docking studies between the mGlu5 allosteric pocket and fragment library were followed. Despite 
the relatively weak interactions between the fragments and the surrounding residues, the 
aggregation of fragments in different regions inside the pocket could be observed and analyzed. 
Then, fragments linking was adopted as the strategy for processing the fragments, based on their 
spatial positions inside the pocket. After the generation of lead compounds, docking studies 
between newly created lead compounds and the mGlu5 allosteric pocket were performed to identify 
hits. Finally, multiple docking algorithms, enrichment test, and QSAR model simulation were 
combined to virtually validate the effectiveness of selected hits. 20 in silico synthesized 
compounds were reported to be potential mGlu5 allosteric modulators. Details are described in the 
following paragraphs. 
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Figure 6. Study design and strategies for designing novel mGlu5 allosteric modulators 
 
3.2 THE ESTABLISHMENT OF FRAGMENT LIBRARY 
 
27262 GPCR allosteric modulators were downloaded from ASD. RECAP Analysis in 
ChemAxon’s Fragmenter (https://www.chemaxon.com) was used to generate our fragment 
library. “Rule of three”(57, 58) rather than “Rule of five”(59) was used here for guiding the 
selection of ideal fragments. The contents for “Rule of three” included molecular weight < 300, 
hydrogen bond donors ≤ 3, hydrogen bond acceptors ≤ 3, and cLogP ≤ 3. After deleting duplicate 
items, a library with 863 fragments was generated. Among them, 47 fragments had  molecular 
weights over 300; 3 fragments had over 3 hydrogen bond donors; 56 fragments had over 3 
hydrogen bond acceptors; and 72 fragments had their LogP(o/w) values over 3.  Table 2 
demonstrates top ten most frequently appeared fragments with corresponding properties as an 
example. A comparison between the fragment library we generated and the Maybridge fragment 
library was conducted. MACCS Structural Keys were used for calculating the fingerprint of each 
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fragment. Tanimoto Coefficient was set to be 80%. 78% of fragments in the library we generated 
could be matched with items in Maybridge library, while the remaining 22% of fragments may 
contribute to the particularity of GPCR allosteric modulators. 
 
Table 2. Structure and properties for top ten most frequently appeared fragments 
Structure Frequency LogP(o/w) M.W. 
Hydrogen 
bond donor 
Hydrogen 
bond acceptor 
 
407 1.60 94.11 1 1 
 
357 0.56 107.11 0 2 
 
324 0.91 203.20 0 1 
 
197 -0.06 46.07 1 1 
 
188 1.99 124.11 0 1 
 
188 -0.42 153.19 1 3 
 
173 0.99 70.01 0 0 
 
167 -0.10 45.08 1 1 
 
163 2.06 96.10 0 0 
 
162 0.67 79.10 0 1 
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3.3 DOCKING STUDIES OF FRAGMENTS INTO mGlu5 
 
Before docking studies of the fragments we docked the reported NAM, mavoglurant, back to the 
defined allosteric binding site to function as a control for the validation of our docking process. 
Residues from TM2, TM3, TM5, TM6 and TM7 formed the pocket. Gly624, Ile625, Gly628, 
Pro655, Ser805, Val806, and Ser809 were directly involved in the pocket (Fig. 7A). Comparing 
our docking results with the crystal structure of human mGlu5 (PDB entry: 4OO9; resolution, 2.6 
Å; method, X-ray diffraction)(16) in complex with the negative allosteric modulator, mavoglurant 
bound well inside the pocket with the alkyne linker traversing a narrow channel between Tyr659, 
Ser809, Val806, and Pro655. Three hydrogen bonds could be formed between mavoglurant and 
Asn747, Ser805, Ser809 (Fig. 7B). Our docking studies between mavoglurant and the defined 
allosteric binding site provided congruent results with the crystal structure. Identical residues were 
involved in the formation of hydrogen bond interaction (Fig. 7C). The docking result overlapped 
well with the crystallized complex, with the RMSD of ~0.3Å (Fig. 7D), indicating that our docking 
process is relatively reliable.  
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Figure 7. Allosteric binding site of mGlu5 
A. The allosteric binding site (highlighted in salmon pink), which is formed by surrounding 
residues marked in cyan. B. The interaction between mavoglurant and surrounding residues based 
on the spatial information from the reported crystal complex. C. Docking pose and ligand-residue 
interaction predicted through the docking study. D. The overlap of mavoglurant between 
crystallized complex and predicted pose.  
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 Then the generated fragments in our fragment library were docked into the mGlu5 
allosteric binding site. We conducted three independent docking studies for all fragments, and 
found that fragments invariably aggregated into two distinct regions of the binding pocket of 
mGlu5, an upper region and a bottom region (Figs. 8A and 8B).  
 
 
Figure 8. Fragment docking studies 
A. Upper region (highlighted in pink) and bottom region (highlighted in yellow), which are 
connected through a narrow channel and recognized through fragments docking. B. The 
aggregation of fragments inside the allosteric binding site. 
 
The number of fragments for each region was summarized in Fig. 9. Our docking results 
were very consistent across our three independent runs, with ~416 (85%) of fragments in the upper 
region and ~320 (87%) of fragments in the bottom region were repeated in the same region 
throughout the three docking runs. 
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Figure 9. Fragments sorting 
The distribution of fragments towards the upper and bottom regions from three independent 
docking runs. 
 
3.4 IN SILICO SYNTHESIS OF NOVEL COMPOUNDS FROM CATEGORIZED 
FRAGMENTS 
 
A single fragment may bind with low affinity to a protein because of the lower molecular weight, 
which results in a limited amount of ligand-receptor interaction.(60) The combination of the 
fragments from upper and bottom regions is a promising strategy for increasing the affinity of 
binding. RECAP Synthesis in ChemAxon Fragmenter was used to combine the fragments in upper 
region with the fragments in the bottom region. In order to find out whether the docking scores 
can be used as guidance for RECAP Synthesis, a trial was first conducted. A small scale of RECAP 
Synthesis was performed with two sets of fragments: (1) ~600 compounds were generated by 30 
fragments in upper region and 20 in bottom region with the highest docking scores; (2) ~600 
compounds were generated by 30 fragments in upper region and 20 in bottom region with the 
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lowest docking scores, respectively. The distribution of their docking scores (Fig. 10) revealed 
that the combination of fragments with higher docking scores tended to result in compounds with 
better binding affinities. The Mann-Whitney Test showed that asymptotic significance (2-tailed) 
is less than 0.001, which meant these two distributions were significantly different. 
 
 
Figure 10. Distribution of the docking scores for small scale RECAP Synthesis 
Yellow bars represent compounds generated from fragments with highest docking scores. Blues 
bars represent compounds generated from fragments with lowest docking scores. Two-tailed 
Mann-Whitney Test was performed to prove the significant difference between these two 
distributions. 
 
  Then, 9600 novel compounds were generated through the large-scale RECAP Synthesis 
with 120 highest scored fragments in the upper region (Supplementary Table. 1) and 80 highest 
scored fragments in the bottom region (Supplementary Table. 2). Our results showed that 124 in 
silico synthesized compounds had the docking score higher than seven (Supplementary Table. 
3). Since the docking score was expressed as –log10(Kd), as described in Materials and Methods, 
0
20
40
60
80
100
120
140
-1 -0.5 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8
N
u
m
b
er
 o
f 
co
m
p
o
u
n
d
s
Docking score
Distribution of docking scores
24 
 
compound with a docking score higher than seven means that their corresponding predicted Kd is 
less than 10-7 Mol, which is a positive sign for binding affinity. Interestingly, six in silico 
synthesized compounds have higher docking scores than mavoglurant. The structures of top 20 in 
silico synthesized compounds, as well as the mavoglurant, were shown in Table 3. 
 
Table 3. Docking score, binding energy and predicted Ki value for top 20 in silico synthesized compounds.  
No. Structure 
Docking 
score 
Binding 
energy 
Predicted Ki 
1 
F
O
N
N N O
N
 
10.4 -7.7 kcal/mol 1.3 nM 
2 
 
8.9 -7.2 kcal/mol 10.9 nM 
3 
 
8.3 -5.5 kcal/mol 67.3 nM 
4 
 
8.1 -6.1 kcal/mol 132.6 nM 
5 
 
8.1 -5.8 kcal/mol 88.1 nM 
6 
 
8.0 -5.4 kcal/mol 324.2 nM 
7 
 
7.7 -4.7 kcal/mol 545.0 nM 
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8 
 
7.6 -5.1 kcal/mol 225.5 nM 
9 
 
7.6 -4.8 kcal/mol 199.4 nM 
10 
 
7.6 -5.4 kcal/mol -- 
11 
 
7.6 -5.3 kcal/mol 207.0 nM 
12 
 
7.5 -4.5 kcal/mol 130.9 nM 
13 
 
7.5 -4.3 kcal/mol --  
14 
 
7.4 -4.4 kcal/mol -- 
15 
 
7.4 -5.5 kcal/mol -- 
16 
 
7.4 -5.1 kcal/mol -- 
17 
 
7.3 -4.2 kcal/mol 1162.3 nM 
18 
 
7.3 -5 kcal/mol 357.6 nM 
19 
 
7.3 -4.1 kcal/mol -- 
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20 
 
7.3 -4.4 kcal/mol 792.2 nM 
NAM 
 
7.9 -5.9 kcal/mol 
107.0 nM 
(Experimental Ki 
value: 66 nM) 
 
 
 Moreover, we introduced binding energy of molecular docking as a supplementary 
evidence for receptor-ligand interaction by using AutoDock 4.0. The results of top 20 compounds 
can be found in Table 3. A correlation plot was drafted (Fig. 11) to show the relationship between 
the docking score and the binding energy for each compound. All of these 20 in silico synthesized 
compounds had a predicted negative binding energy, which had a high correlation with the docking 
scores,(61, 62) providing the evidence that the docking studies with SYBYL-X 1.3 and AutoDock 
4.0 were consistent with each other. 
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Figure 11. Correlation plot for docking score and binding energy 
Red spot represents the docking score and binding energy for mavoglurant. Yellow spots 
represent the docking scores and binding energies for 20 in silico synthesized compounds. 
 
 The binding poses of the highest ranked in silico synthesized compound was compared 
with the reported NAM, mavoglurant. The in silico synthesized compound occupied the identical 
position as mavoglurant (Fig. 7B), forming the hydrogen bond with Ser805 (Fig. 12A). Two 
compounds overlapped very well with the RMSD of 1 Å, as shown in Fig. 12B. Interestingly, our 
docking studies suggest that compound 1, our highest scoring compound proposed by our in silico 
methods, is predicted to form hydrogen bonds with Thr735 and Tyr659, which are not reported for 
mavoglurant. These two additional receptor-ligand interactions might explain the higher docking 
score acquired by the highest ranked in silico synthesized compound than mavoglurant. Whether 
or not these would actually form if compound 1 were synthesized and crystallization attempted 
would be an interesting experiment to conduct. 
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Figure 12. In silico synthesis of potential mGlu5 allosteric modulators 
A. The binding pose of top one in silico synthesized compound. B. Comparison of binding poses 
between top one in silico synthesized compound (pink) and mavoglurant (yellow). 
 
3.5 ENRICHMENT TEST WITH A BENCHMARKING DATASET 
 
Dr. John. J. Irwin and his group generated the Directory of Useful Decoys, Enhanced (DUD-E), 
which is available at http://dude.docking.org. The physical properties used are molecular weight, 
calculated LogP, H-bond donors and acceptors, the number of rotatable bonds and net molecular 
charge in order to build physically similar decoys.(51) A tool (http://decoys.docking.org), which 
is automated and available online could be used for generating the matched decoys for user-
supplied ligands. The reported mGlu5 NAM, mavoglurant, was used as the ligand for decoys 
generation. 71 compounds, including 50 decoys (Supplementary Table. 4), mavoglurant, as well 
as top 20 in silico synthesized compounds were docked into mGlu5 (Fig. 13). Our results showed 
a clear enrichment of NAM and in silico synthesized compounds against 50 decoys. These results 
indicated that 20 in silico synthesized compounds could be enriched with NAM, and were different 
from challenging decoys. 
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Figure 13. The enrichment test with decoys 
The red bar represents the reported negative allosteric modulator, mavoglurant, for mGlu5. Yellow 
bars represent the top 20 in silico synthesized compounds. Blue bars represent the decoys 
generated under DUD-E. 
 
3.6 PREDICTION OF COMPETITION BINDING WITH A QUANTITATIVE 
STRUCTURE-ACTIVITY RELATIONSHIP MODEL 
 
The selectivity of a ligand towards receptor subtypes could be measured with the competitive 
binding assay, which also reveals the percentage and density of each subtype among a certain 
tissue.(63) Competition binding is widely used in testing potential allosteric modulators for GPCRs. 
66 analogs of 1,2-diphenylethyne with existing Ki values were selected from ASD 
(Supplementary Table. 5). Following the method described in the Materials and Methods, a 
QSAR model with 12 descriptors was built:  
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LogKi =-6.81 + 3.11 * BCUT_PEOE_3 - 2.46 * BCUT_SLOGP_3 + 0.46 * b_1rotN - 12.76 * 
b_1rotR - 9.57 * GCUT_PEOE_0 - 4.37 * GCUT_SLOGP_0 + 4.49 * GCUT_SMR_0 - 0.17 * 
Kier3 + 0.06 * PEOE_VSA+5 - 0.03 * SlogP_VSA4 - 0.02 * SMR_VSA0 - 0.02 *SMR_VSA1 
 
Table 4. Descriptors of linear regression analysis 
Notation Descriptors Coefficient 
Contingency 
coefficient 
Cramer’s 
V 
Entropic 
uncertainty 
Linear 
correlation 
Intercept - -6.81 - - - - 
BCUT_PEOE_3 PEOE 
Charge 
BCUT (3/3) 
3.11 0.82 
 
0.41 
 
0.43 
 
0.16 
 
BCUT_SLOGP_3 LogP BCUT 
(3/3) 
-2.46 0.80 
 
0.39 
 
0.40 
 
0.17 
 
b_1rotN Number of 
rotatable 
single bonds 
0.46 0.69 
 
0.27 
 
0.22 
 
 
0.15 
 
b_1rotR Fraction of 
rotatable 
single bonds 
-12.76 0.79 
 
0.37 
 
0.36 
 
0.20 
 
GCUT_PEOE_0 PEOE 
Charge 
GCUT (0/3) 
-9.57 0.81 
 
0.40 
 
0.44 
 
0.29 
 
GCUT_SLOGP_0 LogP GCUT 
(0/3) 
-4.37 0.77 
 
0.35 
 
0.39 
 
0.17 
 
GCUT_SMR_0 Molar 
Refractivity 
GCUT (0/3) 
4.49 0.82 
 
0.41 
 
0.41 
 
0.20 
 
Kier3 Third Kappa 
shape index 
-0.17 0.76 
 
0.33 
 
0.30 
 
0.19 
 
PEOE_VSA+5 Total 
positive 5 
vdw surface 
area 
0.06 0.66 
 
0.25 
 
0.30 
 
0.19 
 
SlogP_VSA4 Bin 4 SlogP 
(0.10, 0.15) 
-0.03 0.78 
 
0.36 
 
0.36 
 
0.20 
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SMR_VSA0 Bin 0 SMR 
(0.000, 
0.110) 
-0.02 0.72 
 
0.30 
 
0.32 
 
0.16 
 
SMR_VSA1 Bin 1 SMR 
(0.110,0.260) 
-0.02 0.73 
 
0.31 
 
0.28 
 
0.25 
 
 
 Table 4 shows the calculated descriptors for each molecule, the descriptors coefficients, 
contingency coefficient, Cramer’s V, entropic uncertainty, and linear correlation. A correlation 
plot between the predicted LogKi values and experimental LogKi values was shown in Fig. 14. 
With a correlation coefficient of 0.82 and a cross-validated correlation coefficient of 0.74, the 
established QSAR model was acceptable.(64) This model was used to predict the Ki values for 14 
compounds among the top 20 in silico synthesized compounds, as listed in Table 3. Compounds 
10, 13-16, and 18 were excluded from the prediction with this QSAR model, because they have 
distinctive structural features towards 1,2-diphenylethyne analogs. The predicted values for 14 
compounds are ranging from 1.3 nM to 1162.3 nM. Although discrepancies do exist, generally 
speaking, these data are congruent with their docking scores and binding energies, indicating that 
these compounds are potential mGlu5 allosteric modulators.  
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Figure 14. Correlation plot for quantitative structure-activity relationship model 
Blue spots represent for items in training set. Yellow spots represent for items in test set. The root 
mean square error is 0.49. The correlation coefficient is 0.82. The cross-validated RMSE is 0.60. 
The Cross-validated R2 is 0.74. 
 
3.7 VALIDATION WITH PAINS-REMOVER AND TOXTREE 
 
PAINS-Remover is designed and constructed to remove the Pan Assay Interference Compounds 
(PAINS) from screening libraries.(65) The top 20 in silico synthesized compounds listed in Table 
3 were tested by “Pan Assay Interference Compounds” (PAINS, www.cbligands.org/PAINS/), 
and all compounds passed the filter. Toxtree (http://toxtree.sourceforge.net/index.html) is a 
software to estimate the toxic hazard through decision tree approach.(66) All these top 20 in silico 
synthesized compounds were tested with Toxtree, and all of them had the same level of estimated 
toxic hazard with the reported NAM, mavoglurant.  
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3.8 THE EFFECTS ON LIGANDS AND FRAGMENTS BINDING CAUSED BY THE 
ROTATION OF TRP785 
 
The Trp785 on TM6 is highly conserved, which is similar to the central toggle switch in class A 
GPCRs. The different conformations of Trp785 could be observed between different crystal 
models due to the cocrystallization with different chemotypes. John A. Christopher and his group 
cocrystallized the mGlu5 with HTL14242 and another molecule in the series in 2015. Their crystal 
model of mGlu5 (PDB entry: 5CGD) has a different Trp785 conformation (Figs. 15A and 15A). 
The evaluation of ligands and fragments binding between these two models were performed to 
illustrate the effects caused by the rotation of a critical residue Trp785. Trp785 rotates out of the 
allosteric binding pocket on 4OO9, which results in a relatively large pocket, especially for the 
upper region (Fig. 15A). While for 5CGD, the Trp785 rotates into the allosteric binding pocket, 
which narrows down the space inside. One hydrogen bond could be formed between Trp785 and 
Ser809 in 5CGD, which further limits the size of the substructures for ligands to the top (Fig. 15B). 
The docking study between the mavoglurant and 5CGD shown that the saturated bicyclic ring 
system was no longer favored in the upper region due to the severe collision with Trp785. Instead, 
the aromatic ring on mavoglurant was placed in the upper region with potential hydrophobic 
interactions with rings system on Trp785, and the saturated bicyclic ring system was placed in the 
bottom region (Figs. 15C and 15D). This pose of mavoglurant was not favored by the allosteric 
binding pocket with a docking score of 4.5. The docking studies between 5CGD and 80 highest 
scored fragments in the bottom region, as well as 120 highest scored fragments in upper region 
were followed. The aggregation of fragments in the bottom region remained relatively well. Fig. 
15E shows that the rotation of Trp785 has limited influence on the fragments aggregation in the 
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bottom region. Although some big fragments may invade into the upper region, the same situations 
could be observed with 4OO9, because of the size of these big fragments. Fig. 15F shows that the 
aggregation of fragments in the upper region can no longer been maintained, especially for big 
fragments. The fragments that used to be categorized in the upper region tend to distribute among 
both upper and bottom regions in 5CGD.  
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Figure 15. Assessment on the rotation of Trp785 
A. Extracellular view on the mGlu5 allosteric binding pocket from 4OO9. B. Extracellular view 
on the mGlu5 allosteric binding pocket from 5CGD. C. D. Extracellular view and parallel to the 
membrane view on the binding pose of mavoglurant inside 5CGD according to the molecular 
docking. E. F. Distribution of categorized fragments in the allosteric binding pocket of 5CGD.  
 
The distribution of fragments (Fig. 16) shown that the bottom region is favored by the 
majority of the fragments. Although the overall properties of the upper region remain hydrophobic, 
but the rotation of Trp785 significantly affects the shape of the upper region. The dramatic 
conformational changes on critical residues would have unignorable effects toward the 
effectiveness of the computational fragment linking described in this paper. Fragment growth and 
fragment merge would be alternative methodologies for novel compounds generation using the 
model 5CGD. Based on the identified fragment hits, linkers and functional groups can be 
introduced to improve the chemical physical properties and drug likability. These works may 
beyond the scope of this paper, and 4OO9 was focused to illustrate the study approach. 
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Figure 16. Fragments sorting based on 5CGD 
The distribution of fragments towards the upper and bottom region of 5CGD. Blue bars represent 
the number of fragments in the upper region. Orange bars represent the number of fragments in 
the bottom region. 
 
4.0 DISCUSSION 
 
In order to further validate our in silico synthesized compounds, we tried to find out whether there 
are existing mGlu5 allosteric modulators that are structurally similar to our in silico synthesized 
compounds.  
A similarity search was performed on SciFinder (scifinder.cas.org) using compound 1, 
which is the most potent one according to our prediction, as listed on Table 3. The search was 
started with chemical structures and the search type was similarity. The hits with tanimoto 
coefficients over 85% were selected for further analysis. Interestingly, we identified one 
compound (CAS Number: 1197356-89-0), which is 90% similar towards compound 1, to be 
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almost identical towards compound 6 (97%) listed on Table 3. The only difference between 
1197356-89-0 and compound 6 is the substitution on the benzene ring (Fig. 17A), with compounds 
6 featuring chlorine substitution instead of a fluorine. 1197356-89-0 is a compound that first 
published on a US patent, Piperazine Metabotropic Glutamate Receptor Negative Allosteric 
Modulators for Anxiety/Depression, US 2009/0325964 A1. A competitive binding assay, that 
assesses compounds’ ability to displace MPEP from Hek-293 cell membrane expressing rat mGlu5 
receptors, was used to identify the compounds’ activity in that patent(67). Median Ki value for 
1197356-89-0 is 20 nM (LogKi = 1.30), while our prediction for compound 6 is 324.2 nM (LogKi 
= 2.51). Since logarithmic transformation was used in our QSAR model simulation, the difference 
in absolute Ki value is reasonable and acceptable. The promising biological activity of 1197356-
89-0 demonstrates that our method for in silico design can identify promising chemotypes for 
targets of interest when an existing crystal structure is available to build a model around. We 
further assessed whether the difference between the chlorine and fluorine would be the key 
component for the activity. It is known that fluorine could function as a hydrogen bond acceptor 
to intermediate receptor-ligand interactions. But for chlorine, there is almost no reported role in 
hydrogen bond interactions. 1197358-18-1, which is another compound in that patent, has chlorine 
connected towards the benzene ring (Fig. 17A). The major difference between 1197358-18-1 and 
1197356-89-0 is the substitution on the piperazine ring. For 1197358-18-1, a pyridine is attached, 
while for 1197356-89-0, a pyrimidine is attached. Median Ki value for 1197358-18-1 is 3 nM 
(LogKi = 0.48), which shows that the change from fluorine to chlorine does not decrease the 
allosteric regulation potency. Among our in silico synthesized compounds, with an additional 
methyl group on pyridine, compound 7 listed on Table 3 shares 96% similarity towards 1197358-
18-1 (Fig. 17A). The predicted Ki value for compound 7 is 545.0 nM (LogKi = 2.73). So, the 
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potency of 1197358-18-1 turns out to be another evidence to support our in silico design. And the 
consistency between predicted Ki value and experimental data shows our evaluation is reliable to 
some extent. Through searching the original allosteric modulator database, which used for our 
fragments generation, there are no identical structures to these two compounds in patent. Although 
similar compounds do exist, but they share a low tanimoto coefficient.  
 
A 
 
B 
 
C 
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Figure 17. Structural comparison between in silico synthesized compounds and existing compounds with known 
mGluR allosteric activities. 
Comparisons were circled with dashed lines in red, blue, and pink colors. The major difference 
inside each group was circled with the same color as their group. The CAS number for patented 
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compounds and the corresponding number for in silico synthesized compounds are listed under 
each structure.  
Meanwhile, since compounds 10, 13-16, and 18 have distinctive structures to 1,2-
diphenylethyne analogs and piperazine scaffold described in the above mentioned patient, 
similarity searches for them on Scifinder were continued. 1312414-34-8, which shares 93% 
similarity with compound 10, is a compound that published on a US patent, Bicyclic Thiazoles as 
Allosteric Modulators of Mglur5 Receptors, US 2012/0258955 A1.(68) 1312414-34-8 was tested 
with functional assay, and the pEC50 value is 5.29. Compound 10 has one additional methoxy 
group connected with the aromatic ring, when compared with 1312414-34-8 (Fig. 17B). 879873-
30-0 is a compound that included on a US patent, Novel Thieno-Pyridine and Thieno-Pyrimidine 
Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors, US 
20070275984 A1.(69) 879873-30-0 shares 97% similarity towards compound 14. Compound 14 
has one additional methyl group connected with alkane chain (Fig. 17C). [35S]GTPγS binding 
assay was performed to assess the allosteric activities. 879873-30-0 left-ward shifts the agonist 
mGlu2 concentration-response curve by 2-3.5 folds. Compounds 15/16 share same O-benzyl 
nicotinamide scaffold. The difference is the aromatic or alkane substitution connected to the 
peptide bond. 1276013-84-3, which shares 92% similarity with compound 15, is published on a 
US patent, O-benzyl Nicotinamide Analogs as Mglur5 Positive Allosteric Modulators, US 
2011/0183980 A1 (Fig. 17D).(70) The EC50 (nM) for 1276013-84-3 recorded on the patent is 120. 
Compound 19 shares same 3-cyano-pyridone scaffold with 950199-70-9 with an 83% similarity 
(Fig. 17E). 950199-70-9 is listed on the a US patent, 1, 4-Disubstituted 3-Cyano-Pyridone 
Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors, US 
2014/0315903 A1.(71) The pEC50 of 950199-70-9 for the GTPγS-PAM is 6.7. For compound 13, 
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it shares 83% similarity with 36295-38-2 (Fig. 17F). Dr. Rosaria Gitto’s group reported that N-
substituted isoquinoline derivatives could be functioned as potential AChE inhibitors. But, there 
is no reported activities on metabotropic glutamate receptors for N-substituted isoquinoline 
derivatives, as 36295-38-2.  
The recall of compounds with existing scaffolds and reported effects on mGluR shown 
that the approach we generated is feasible. And the discovery of compounds with unreported 
activities on mGluR revealed that our approach is doable for exploring and designing novel 
compounds. 
 
5.0 CONCLUSION 
 
In this study, we demonstrated a case study of designing allosteric modulators on metabotropic 
glutamate receptor 5 using in silico fragment-based novel compounds design. A GPCR allosteric 
modulator specific fragment library was generated, which could be used for future studies. Various 
computational methodologies, including benchmarking dataset validation, docking studies, 
QuaSAR model simulation, etc. were used to construct the in silico compounds and validate the 
effectiveness of this lead generation strategy. The effects associated with the rotation of toggle 
switch, Trp785, were considered and evaluated. The dramatic conformational changes on critical 
residues would have unignorable effects toward the effectiveness of the computational 
methodology described in this paper. The determination of using one model or combining two or 
more models should be specified at the beginning of the study design. Among the top 20 in silico 
synthesized compounds, as listed in Table 2, diversified structures could be observed. Through 
the compound similarity search on the Scifinder, multiple patents were identified to contain 
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compounds that have similar structural features with our in silico design. Series of compounds 
with reported mGluR allosteric activities were recurred in this case study for designing mGlu5 
allosteric modulators. The in silico designed compounds with reported scaffolds may fill SAR 
holes in the known, patented series of mGlu5 modulators. And the recall of compounds with 
existing scaffolds and reported effects on mGluR shown that the approach we generated is feasible. 
Meanwhile, the generation of compounds without reported activities on mGluR indicates that our 
approach is doable for exploring and designing novel compounds. The medicinal chemistry 
synthesis for these in silico compounds is in progress in our laboratory, and we will perform the 
experiments to confirm our predictions in the future to find out whether they (1) are mGlu5 
allosteric modulators, (2) retain the ranking order the same way as our prediction, (3) have better 
activities than known modulators or not in a head-to-head comparison. Our case study on 
designing allosteric modulators on mGlu5 suggested that this computational fragment-based 
approach is a reliable and powerful methodology for facilitating the future compounds design 
processes.  
 
6.0 FUTURE PROSPECTIVE 
 
6.1 METABOTROPIC GLUTAMATE RECEPTOR 5 ALLOSTERIC REGULATION 
 
In the current study, 20 in silico synthesized compounds were designed and predicted to be 
potential allosteric modulators on mGlu5. Computational simulation and prediction do provide 
evidences for validating the results, but the neglect of experimental verification may lose the 
confidence for the effectiveness of this established computational approach. To further validate 
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the allosteric activity of the in silico synthesized compounds, [35S]GTPγS binding assay would 
be conducted. In this assay, upon activation of the GPCR, the receptor changes conformation 
exposing a binding site for a G-protein complex. Once this G-protein complex is bound, the Gα 
protein can release GDP and bind GTP. Allosteric modulators would have influences on 
orthosteric activities, which would consequently affect the amount of GDP released and GTP 
bound.  
The development of bitopic compounds is another attractive area of research. Combining 
the high affinity, through orthosteric regulation, and the high selectivity, through allosteric 
regulation, bitopic compounds would possess promising biological properties. Linkers could be 
designed and introduced between mGlu5 orthosteric ligands and allosteric modulators. 
Computational methodologies and biological assays could be combined to verify the activity. 
Further modifications could be continued to increase the affinity and efficacy of newly designed 
compounds. Although for class C GPCRs the orthosteric site and allosteric site are usually distant 
from each other, the design of bitopic ligands is a meaningful attempt for adopting a novel strategy 
of compounds design. 
 
6.2 CANNABINOID RECEPTOR 2 ALLOSTERIC REGULATION 
 
The case study of designing allosteric modulators on mGlu5 provided the confidence, to some 
extent, that the computational fragment-based approach is a novel and productive strategy for 
generating modulators and studying GPCRs’ allosteric regulation. There are two types of 
cannabinoid receptors, type 1 and type 2. Cannabinoid receptor 1 (CB1) is mainly distributed in 
the brain and central nervous system, while cannabinoid receptor 2 (CB2) is mostly located in the 
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peripheral organs. CB2 is a vital target for treating autoimmune, osteoporosis, immune system 
cancer, and drug abuse. Designing CB2 allosteric modulators would be an alternative and 
considerable approach in this field of research.  
A CB2 homology model has been constructed based on the crystalized structure of CB1 
(PDB entry: 5TGZ) which is recently reported in 2016 from Zhi-Jie Liu’s group. The orthosteric 
and allosteric binding pocket on CB2 were predicted and verified with reported CB2 selective 
ligands and modulators. With the established computational fragment-based approach, novel CB2 
allosteric modulators could be designed and tested. Biological assays, to be specific, [35S]GTPγS 
binding assay would be conducted to validate the predicted allosteric activities. Furthermore, the 
development of CB2 selective bitopic ligands can be followed. Considering that cannabinoid 
receptors are belonging to class A GPCRs that have their orthosteric and allosteric pockets adjacent 
and both located in the transmembrane domain, developing bitopic ligands is promising. 
 
7.0 APPENDIX 
 
7.1 120 HIGHEST SCORED FRAGMENTS IN THE UPPER REGION 
 
Structure, frequence, molecular weight, logP (o/w), number of hydrogen bond acceptors, and 
number of hydrogen bond donors of 120 highest scored fragments in the upper region are 
summarized in Supplementary Table 1. 
 
Supplementary table 1. 120 highest scored fragments in the upper region 
No. Structure Frequence LogP(o/w) M.W. 
Hydrogen 
bond donor 
Hydrogen 
bond acceptor 
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1 
 
6 1.85 215.09 2 1 
2 
 
6 1.78 279.73 1 2 
3 
 
6 0.29 206.65 2 2 
4 
 
6 2.81 281.76 1 2 
5 
 
6 1.27 113.55 0 1 
6 
 
6 1.50 214.15 3 3 
7 
 
6 2.76 297.29 0 1 
8 
 
6 1.91 260.29 0 2 
9 
 
6 2.51 311.36 0 2 
10 
 
6 0.62 247.25 0 3 
11 
 
6 2.34 270.26 1 2 
12 
 
6 3.08 315.27 2 3 
13 
 
6 1.23 97.09 0 1 
46 
 
14 
 
6 2.16 161.25 1 1 
15 
 
6 2.14 204.32 1 1 
16 
 
6 1.04 109.13 0 1 
17 
 
6 1.42 149.19 0 1 
18 
 
6 3.26 284.40 0 2 
19 
 
6 3.43 280.37 0 2 
20 
 
6 1.97 259.35 0 2 
21 
 
6 4.08 247.30 0 2 
22 
 
6 1.52 218.28 1 3 
23 
 
6 2.71 208.26 2 3 
24 
 
6 2.26 233.30 1 2 
25 
 
6 2.09 297.25 1 4 
47 
 
26 
 
6 1.90 231.30 0 2 
27 
 
6 0.51 177.25 1 2 
28 
 
6 1.11 148.21 1 2 
29 
 
6 1.21 201.27 1 3 
30 
 
6 0.59 177.25 1 2 
31 
 
6 2.29 121.18 0 1 
32 
 
6 1.81 256.36 2 4 
33 
 
6 0.95 238.27 0 3 
34 
 
6 0.47 267.27 1 3 
35 
 
6 0.05 213.30 1 3 
36 
 
6 0.70 255.32 2 3 
37 
 
6 2.27 176.24 1 1 
38 
 
6 1.90 117.15 0 1 
39 
 
6 0.77 124.14 1 1 
40 
 
6 -0.19 89.09 1 1 
41 
 
6 1.57 122.12 0 2 
48 
 
42 
 
6 2.03 189.21 0 2 
43 
 
6 1.49 131.13 0 2 
44 
 
6 -0.06 214.23 0 4 
45 
 
6 1.58 122.12 2 2 
46 
 
6 1.10 93.13 0 1 
47 
 
6 -0.63 95.10 1 2 
48 
 
6 0.67 96.08 0 1 
49 
 
6 0.53 124.14 1 1 
50 
 
6 0.66 112.13 1 1 
51 
 
5 1.47 145.99 1 0 
52 
 
5 3.01 351.74 1 2 
53 
 
5 1.83 127.57 1 0 
54 
 
5 2.80 126.59 0 0 
55 
 
5 3.25 328.76 0 3 
56 
 
5 2.85 194.64 0 1 
57 
 
5 2.50 112.56 0 0 
58 
 
5 1.67 255.24 1 2 
49 
 
59 
 
5 3.55 373.34 0 4 
60 
 
5 1.89 299.26 2 5 
61 
 
5 2.09 312.30 1 1 
62 
 
5 0.77 194.21 2 2 
63 
 
5 1.35 125.15 1 1 
64 
 
5 2.85 312.30 0 3 
65 
 
5 4.88 242.22 0 1 
66 
 
5 1.91 260.29 0 2 
67 
 
5 4.69 224.23 0 1 
68 
 
5 3.42 225.22 0 2 
69 
 
5 4.69 224.23 0 1 
70 
 
5 1.23 97.09 0 1 
71 
 
5 0.38 55.08 0 1 
72 
 
5 1.53 107.16 1 0 
50 
 
73 
 
5 1.23 93.13 1 0 
74 
 
5 1.59 124.14 1 2 
75 
 
5 2.81 312.37 1 4 
76 
 
5 -0.57 194.24 1 3 
77 
 
5 -0.52 87.08 1 1 
78 
 
5 0.85 121.14 1 1 
79 
 
5 2.86 352.35 1 4 
80 
 
5 2.66 294.31 0 3 
81 
 
5 -0.77 152.18 1 2 
82 
 
5 2.66 279.29 0 1 
83 
 
5 2.78 279.29 2 3 
84 
 
5 1.84 123.11 0 0 
85 
 
5 -0.08 60.05 2 2 
86 
 
5 -1.03 73.10 2 2 
51 
 
87 
 
5 2.63 323.38 1 3 
88 
 
5 0.56 234.24 3 4 
89 
 
5 0.93 109.13 2 1 
90 
 
5 1.90 108.14 1 1 
91 
 
5 0.33 310.36 2 4 
92 
 
5 1.27 138.12 3 3 
93 
 
5 0.23 120.16 1 2 
94 
 
5 -0.09 188.23 1 3 
95 
 
5 -0.09 188.23 1 3 
96 
 
5 1.03 126.16 1 1 
97 
 
5 1.67 156.25 1 1 
98 
 
5 2.95 257.36 0 2 
99 
 
5 0.95 238.27 0 3 
100 
 
5 2.20 286.31 1 3 
52 
 
101 
 
5 1.90 262.31 0 2 
102 
 
5 0.45 227.33 1 3 
103 
 
5 0.36 225.32 1 3 
104 
 
5 1.02 178.22 1 3 
105 
 
5 0.04 97.07 0 2 
106 
 
5 2.60 201.25 1 1 
107 
 
5 1.04 128.56 1 1 
108 
 
5 1.56 141.56 0 2 
109 
 
5 1.06 179.10 0 2 
110 
 
5 0.08 138.13 3 3 
111 
 
5 -1.00 140.10 4 5 
112 
 
5 0.74 111.10 2 3 
113 
 
5 -0.52 68.08 2 2 
114 
 
5 1.14 93.13 0 1 
115 
 
5 1.48 112.15 0 1 
116 
 
5 1.02 72.11 0 1 
117 
 
5 1.46 156.21 0 2 
118 
 
5 1.89 157.60 1 1 
119 
 
5 0.50 121.14 0 2 
53 
 
120 
 
5 0.40 74.08 2 2 
 
 
7.2 80 HIGHEST SCORED FRAGMENT IN THE BOTTOM REGION 
 
Structure, frequence, molecular weight, logP (o/w), number of hydrogen bond acceptors, and 
number of hydrogen bond donors of 80 highest scored fragments in the bottom region are 
summarized in Supplementary Table 2. 
 
Supplementary table 2. 80 highest scored fragments in the bottom region 
No. Structure Frequence LogP(o/w) M.W. 
Hydrogen 
bond donor 
Hydrogen 
bond acceptor 
1 
 
6 1.54 126.18 0 1 
2 
 
6 0.90 224.65 1 2 
3 
 
6 1.52 137.11 1 2 
4 
 
6 2.14 142.10 0 1 
5 
 
6 2.20 122.17 0 1 
6 
 
6 1.90 152.19 0 2 
7 
 
6 1.33 218.23 0 1 
8 
 
6 0.26 115.18 2 2 
54 
 
9 
 
6 -1.97 196.10 3 6 
10 
 
6 1.03 137.14 1 3 
11 
 
6 3.26 235.29 2 1 
12 
 
6 1.00 217.25 1 3 
13 
 
6 2.26 231.13 1 1 
14 
 
6 2.36 110.13 0 0 
15 
 
6 1.57 103.12 0 1 
16 
 
6 0.88 326.38 1 4 
17 
 
6 3.63 120.20 0 0 
18 
 
6 3.37 352.72 1 3 
19 
 
6 2.25 114.09 0 0 
20 
 
6 -1.07 117.15 2 3 
21 
 
6 0.88 326.38 1 4 
55 
 
22 
 
6 1.82 257.32 1 3 
23 
 
6 1.46 121.18 1 1 
24 
 
6 2.33 309.35 1 3 
25 
 
6 3.05 175.01 0 1 
26 
 
6 1.09 152.15 1 3 
27 
 
6 1.24 203.25 1 2 
28 
 
6 0.33 138.17 1 2 
29 
 
5 3.13 147.00 0 0 
30 
 
5 2.21 161.13 1 0 
31 
 
5 2.84 146.11 0 0 
32 
 
5 1.30 162.11 1 1 
33 
 
5 1.42 111.12 1 0 
34 
 
5 2.21 114.09 0 0 
35 
 
5 1.86 138.17 0 2 
36 
 
5 1.18 153.18 1 2 
37 
 
5 3.27 207.23 0 2 
38 
 
5 2.00 208.22 0 3 
56 
 
39 
 
5 1.60 94.11 1 1 
40 
 
5 3.95 124.23 0 0 
41 
 
5 1.15 87.17 1 1 
42 
 
5 1.57 107.16 1 0 
43 
 
5 2.29 196.21 1 3 
44 
 
5 0.73 110.11 0 1 
45 
 
5 0.96 196.27 2 1 
46 
 
5 1.69 193.27 1 2 
47 
 
5 1.11 168.14 1 1 
48 
 
5 3.13 147.00 0 0 
49 
 
5 1.49 185.27 1 2 
50 
 
5 -0.01 101.15 1 2 
51 
 
5 2.73 148.21 0 1 
52 
 
5 1.11 140.18 0 2 
53 
 
5 0.62 129.20 2 2 
54 
 
5 0.02 115.18 2 2 
55 
 
5 -0.29 216.26 3 4 
56 
 
5 1.03 137.14 1 3 
57 
 
57 
 
5 1.87 247.69 0 3 
58 
 
5 3.90 241.68 0 2 
59 
 
5 3.07 242.66 0 3 
60  5 0.75 48.06 0 0 
61 
 
5 1.17 164.25 1 1 
62 
 
5 1.65 243.29 1 3 
63 
 
5 1.25 135.17 1 1 
64 
 
5 0.69 233.30 1 4 
65 
 
5 0.38 205.24 2 3 
66 
 
5 4.28 309.39 1 2 
67 
 
5 3.03 118.18 0 0 
68 
 
5 1.59 133.19 1 1 
69 
 
5 -0.38 170.19 2 3 
70 
 
5 2.22 167.64 1 1 
58 
 
71 
 
5 3.34 345.79 0 2 
72 
 
5 0.99 247.32 1 4 
73 
 
5 -1.31 125.13 1 3 
74 
 
5 2.43 179.12 1 0 
75 
 
5 1.26 277.20 3 3 
76 
 
5 0.45 187.22 1 2 
77 
 
5 -0.38 192.27 1 3 
78 
 
5 0.25 163.22 1 2 
79 
 
5 2.13 140.21 0 1 
80 
 
5 1.82 121.18 0 0 
 
 
7.3 124 IN SILICO SYNTHESIZED COMPOUNDS WITH DOCKING SCORE OVER 7 
 
Structure, molecular weight, logP (o/w), number of hydrogen bond acceptors, and number of 
hydrogen bond donors of 124 in silico synthesized compounds with docking score over 7 are 
summarized in Supplementary Table 3. 
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Supplementary table 3. 124 in silico synthesized compounds with docking score over 7 
No. Structure  M.W. LogP(o/w) 
H-bond 
acceptor 
H-bond 
Donor 
1 
 
302.20 3.34 2 1 
2 
 
408.29 6.10 2 2 
3 
 
283.80 4.39 1 0 
4 
 
412.94 3.47 5 1 
5 
 
370.86 2.77 4 2 
6 
 
285.82 4.81 1 0 
7 
 
317.82 3.98 3 0 
8 
 
368.86 4.18 3 1 
9 
 
433.90 2.99 4 0 
10 
 
416.91 4.07 3 0 
60 
 
11 
 
442.91 4.81 3 0 
12 
 
326.83 5.04 2 1 
13 
 
443.98 6.03 2 1 
14 
 
377.83 4.22 3 1 
15 
 
360.84 5.35 2 1 
16 
 
496.02 5.49 6 2 
17 
 
481.94 3.67 3 1 
18 
 
434.89 2.17 5 0 
19 
 
444.97 5.21 3 1 
61 
 
20 
 
314.31 2.12 2 2 
21 
 
296.25 3.03 3 2 
22 
 
367.33 3.99 3 1 
23 
 
308.30 3.83 2 1 
24 
 
343.28 2.50 3 1 
25 
 
348.33 0.64 4 2 
26 
 
370.41 1.72 3 1 
27 
 
310.37 1.69 3 1 
28 
 
310.37 1.69 3 1 
29 
 
242.25 2.67 2 0 
30 
 
246.24 2.25 3 2 
62 
 
31 
 
366.39 4.29 3 1 
32 
 
382.34 3.04 3 3 
33 
 
297.29 5.07 0 1 
34 
 
329.29 4.24 2 1 
35 
 
333.29 2.12 4 1 
36 
 
257.26 3.57 3 0 
37 
 
434.45 3.98 3 0 
38 
 
242.22 4.88 1 0 
39 
 
260.29 1.91 2 0 
40 
 
396.37 3.20 3 3 
63 
 
41 
 
369.30 2.98 4 4 
42 
 
423.39 2.81 5 4 
43 
 
417.44 2.52 4 0 
44 
 
427.52 5.56 2 1 
45 
 
311.36 2.51 2 0 
46 
 
247.25 0.62 3 0 
47 
 
441.45 2.54 5 0 
48 
 
255.26 1.83 2 1 
49 
 
304.34 3.30 1 1 
50 
 
375.38 5.18 2 2 
51 
 
416.46 3.79 3 0 
64 
 
52 
 
414.48 3.98 3 0 
53 
 
204.32 2.14 1 1 
54 
 
257.33 3.77 2 0 
55 
 
274.32 3.76 4 0 
56 
 
466.50 4.56 5 1 
57 
 
272.30 2.09 3 1 
58 
 
370.45 3.01 4 1 
59 
 
388.47 4.34 3 0 
60 
 
342.44 4.22 3 1 
61 
 
376.46 4.53 3 1 
65 
 
62 
 
316.36 4.34 3 0 
63 
 
312.37 2.81 4 1 
64 
 
300.36 2.07 3 2 
65 
 
355.42 2.18 5 2 
66 
 
400.44 1.10 5 0 
67 
 
284.36 3.06 2 1 
68 
 
370.45 3.01 4 1 
69 
 
393.44 3.40 4 1 
70 
 
362.43 4.44 3 1 
71 
 
356.42 2.74 4 0 
66 
 
72 
 
306.36 2.93 3 0 
73 
 
268.36 2.90 1 2 
74 
 
345.45 -0.58 4 1 
75 
 
325.42 0.54 3 1 
76 
 
383.45 2.18 4 0 
77 
 
266.34 2.51 1 1 
78 
 
410.52 4.13 3 1 
79 
 
326.40 4.72 2 1 
80 
 
368.44 4.30 2 3 
81 
 
352.35 2.86 4 1 
82 
 
259.35 1.97 2 0 
67 
 
83 
 
395.49 1.57 5 3 
84 
 
321.40 2.60 3 2 
85 
 
248.33 1.18 2 2 
86 
 
261.36 2.43 2 1 
87 
 
320.39 2.96 3 1 
88 
 
305.33 3.66 3 2 
89 
 
471.58 3.49 3 2 
90 
 
309.35 2.33 3 1 
91 
 
310.36 0.33 4 2 
68 
 
92 
 
432.52 3.44 4 2 
93 
 
359.35 0.91 4 4 
94 
 
402.43 0.49 5 2 
95 
 
454.43 1.73 4 1 
96 
 
435.46 -1.39 6 3 
97 
 
362.45 2.44 4 3 
98 
 
235.29 3.26 1 2 
99 
 
237.30 1.01 2 1 
100 
 
300.36 0.02 3 0 
101 
 
241.29 1.99 1 0 
102 
 
336.39 2.16 2 1 
69 
 
103 
 
478.56 0.32 6 2 
104 
 
422.55 3.03 4 1 
105 
 
357.52 5.42 2 0 
106 
 
253.37 1.83 2 1 
107 
 
288.42 2.70 1 1 
108 
 
278.31 1.76 3 1 
109 
 
440.48 1.89 5 2 
110 
 
366.41 1.69 4 0 
111 
 
398.46 3.81 3 0 
112 
 
290.34 1.67 3 1 
70 
 
113 
 
396.50 2.29 5 3 
114 
 
311.45 4.33 2 1 
115 
 
343.45 3.49 4 1 
116 
 
227.33 0.45 3 1 
117 
 
433.54 2.45 5 1 
118 
 
473.48 2.46 5 1 
119 
 
225.32 0.36 3 1 
120 
 
330.46 1.43 3 0 
121 
 
341.44 3.05 2 0 
122 
 
302.44 3.30 1 1 
123 
 
276.36 2.46 2 1 
124 
 
300.30 3.23 2 1 
71 
 
 
7.4 DECOYS INVOLVED IN THE ENRICHMENT TEST 
 
Structure, molecular weight, logP (o/w), number of hydrogen bond acceptors, number of hydrogen 
bond donors, and number of rotatable bonds of decoys are summarized in Supplementary Table 
4. 
 
Supplementary table 4. Properties of mavoglurant and benchmarking decoys 
No. Structures M.W. LogP(o/w) 
H-bond 
acceptor 
H-bond 
donor 
Number of 
rotatable bonds 
C94605550 
 
349.26 2.61 2 1 2 
C94603839 
 
349.26 2.23 2 1 3 
C50892585 
 
346.18 3.94 2 1 2 
C40285632 
 
346.18 3.86 2 1 2 
C89233694 
 
351.27 3.20 3 2 3 
C94730376 
 
361.04 3.70 3 1 2 
C49773000 
 
348.17 2.69 2 1 3 
72 
 
C54346841 
 
348.17 2.69 2 1 3 
C94672645 
 
345.62 2.99 2 1 3 
C86415567 
 
353.26 3.73 2 1 3 
C18041725 
 
346.23 3.98 4 1 3 
C01435425 
 
368.61 4.28 4 1 2 
C37968541 
 
351.24 3.70 4 1 4 
C91880141 
 
352.23 3.54 4 1 4 
C85807545 
 
353.26 3.05 2 1 3 
C57549951 
 
350.24 3.35 3 1 3 
C85404698 
 
351.24 4.27 0 0 3 
C02957825 
 
375.25 4.14 3 1 2 
73 
 
C20560551 
 
347.28 3.12 0 0 3 
C88086088 
 
351.24 2.97 2 1 3 
C03610264 
 
351.24 3.96 2 1 2 
C86379333 
 
353.26 3.27 2 1 3 
C96842812 
 
371.30 2.66 2 1 2 
C37304332 
 
351.27 3.01 2 1 3 
C22319230 
 
352.89 3.52 2 1 4 
C52306345 
 
353.85 4.17 3 1 3 
C33316201 
 
345.81 4.78 3 1 3 
C00287599 
 
344.80 5.75 4 2 3 
74 
 
C02385249 
 
367.37 3.12 3 1 2 
C19332894 
 
345.46 4.30 3 1 2 
C77543852 
 
347.48 3.65 2 1 5 
C90748008 
 
359.21 3.26 2 1 2 
C97630911 
 
381.22 3.24 2 1 2 
C97605644 
 
375.17 3.95 1 0 2 
C03843779 
 
364.53 4.44 4 1 2 
C66132068 
 
350.46 4.22 2 1 3 
C14480323 
 
374.48 3.33 2 1 3 
75 
 
C38331020 
 
362.51 3.69 3 1 2 
C00759147 
 
361.44 3.75 3 1 2 
C38703321 
 
351.43 3.53 2 1 2 
C89982910 
 
363.55 2.92 3 1 2 
C77549341 
 
347.53 3.08 1 1 5 
C02439112 
 
344.44 3.22 3 1 2 
C39895682 
 
352.44 4.30 3 1 2 
C00296654 
 
345.46 3.03 2 1 3 
C48276740 
 
343.48 2.85 2 1 4 
C55927954 
 
343.50 3.97 1 0 3 
76 
 
C67132597 
 
343.50 3.97 1 0 2 
C12601193 
 
348.35 3.47 2 1 3 
C20715199 
 
362.45 3.37 2 1 2 
nam 
 
313.40 3.86 2 1 4 
 
7.5 Ki VALUE AND PHYSICAL PROPERTIES OF 66 1,2-DIPHENYLETHYNE 
ANALOGS 
 
Structure, Ki value, molecular weight, logP (o/w), number of hydrogen bond acceptors, and 
number of hydrogen bond donors of 66 1,2-diphenylethyne analogs are summarized in 
Supplementary Table 5. 
 
Supplementary table 5. Ki value and physical properties of 66 1,2-diphenylethyne analogs 
No. Structures Ki (nM) M.W. 
LogP 
(o/w) 
H-bond 
acceptor 
H-bond 
Donor 
T1 
 
0.90 242.28 3.44 2 0 
77 
 
T2 
 
11.40 294.35 4.43 2 0 
T3 
 
13.00 193.25 3.77 1 0 
T4 
 
18.00 287.32 3.15 3 0 
T5 
 
32.00 309.32 4.09 2 0 
T6 
 
69.00 272.31 4.09 2 0 
T7 
 
250.00 296.76 3.33 2 0 
T8 
 
255.00 273.29 2.85 3 0 
T9 
 
567.00 351.43 2.95 4 0 
T10 
 
670.00 330.43 4.58 2 0 
T11 
 
3660.00 292.34 2.70 3 0 
T12 
 
6150.00 296.76 3.30 2 0 
78 
 
T13 
 
0.37 224.29 3.21 2 0 
T14 
 
3.50 240.31 2.88 2 0 
T15 
 
5.49 276.36 4.21 2 0 
T16 
 
22.00 291.33 3.90 2 0 
T17 
 
1280.00 290.37 3.51 2 0 
T18 
 
5680.00 324.81 4.10 2 0 
T19 
 
7100.00 264.33 3.44 2 0 
T20 
 
3.40 193.25 3.77 1 0 
T21 
 
29.00 286.33 4.42 2 0 
T22 
 
72.00 286.33 4.42 2 0 
T23 
 
83.00 298.35 3.41 3 0 
79 
 
T24 
 
368.00 331.35 3.82 2 0 
T25 
 
559.00 341.35 3.38 3 0 
T26 
 
720.00 336.46 4.21 2 0 
T27 
 
1930.00 296.39 3.04 2 0 
T28 
 
2740.00 291.35 2.24 3 0 
T29 
 
2950.00 320.39 3.50 3 0 
T30 
 
20.00 193.25 3.77 1 0 
T31 
 
90.00 298.35 3.44 3 0 
T32 
 
1440.00 347.80 4.22 2 0 
T33 
 
1770.00 317.39 2.97 3 0 
T34 
 
3210.00 344.46 5.02 2 0 
T35 
 
7900.00 296.76 3.29 2 0 
80 
 
T36 
 
1.00 226.30 3.16 2 0 
T37 
 
1.70 240.31 2.88 2 0 
T38 
 
33.00 343.76 5.09 2 0 
T39 
 
36.31 193.25 3.77 1 0 
T40 
 
213.00 287.32 3.07 3 0 
T41 
 
252.00 351.43 2.98 4 0 
T42 
 
510.00 304.39 3.84 2 0 
T43 
 
2240.00 331.42 3.41 3 0 
T44 
 
2.70 294.35 4.51 2 0 
T45 
 
17.00 291.33 3.94 2 0 
T46 
 
100.00 324.81 4.14 2 0 
T47 
 
890.00 316.40 4.24 2 0 
81 
 
T48 
 
2840.00 322.43 3.77 2 0 
T49 
 
3300.00 290.37 4.18 2 0 
T50 
 
7600.00 291.35 2.91 3 0 
T51 
 
10.76 275.38 5.51 1 0 
T52 
 
20.00 391.78 6.14 3 0 
T53 
 
28.00 273.34 3.75 2 0 
T54 
 
760.00 262.31 2.70 2 0 
T55 
 
5230.00 350.85 4.87 2 0 
T56 
 
6240.00 263.30 1.43 3 0 
T57 
 
5.65 277.35 2.97 3 0 
T58 
 
10.00 223.27 3.59 2 0 
T59 
 
36.00 193.25 3.77 1 0 
T60 
 
36.00 325.77 4.90 2 0 
82 
 
T61 
 
820.00 276.34 3.04 2 0 
T62 
 
1770.00 286.33 4.38 2 0 
T63 
 
1800.00 290.37 4.18 2 0 
T64 
 
2170.00 268.34 2.23 2 0 
T65 
 
2840.00 286.33 4.38 2 0 
T66 
 
7450.00 276.34 3.00 2 0 
 
7.6 ABBREVIATIONS 
 
ALDR                          Aldose reductase 
ASD                              Allosteric Database 
CCR5                            C-C chemokine receptor type 5 
CD1A                           T-cell surface glycoprotein CD1a 
CNS                              Central nervous system 
CYP                              Cytochrome P450 
DUD                             Directory of useful decoys 
DUD-E                         Directory of useful decoys, enhanced 
ECFP                            Extended Connectivity Fingerprint 
FBDD                           Fragment-based drug discovery 
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FDA                              Food and drug administration 
GABA                          Gamma-Aminobutyric acid 
GDP                             Guanosine diphosphate 
GPCR                           G protein-coupled receptors 
GTP                              Guanosine-5'-triphosphate 
HIV                               Human immunodeficiency virus 
HTS                              High throughput screen 
LGA                              Lamarckian genetic algorithm 
M1AChR                      Muscarinic acetylcholine receptor M1 
mGlu5                           Metabotropic glutamate receptor 5 
MACCS                       Molecular ACCess System 
NAM                            Negative allosteric modulator 
NMR                             Nuclear magnetic resonance 
OXDA                          D-amino-acid oxidase 
PAINS                          Pan Assay Interference Compounds 
PAM                             Positive allosteric modulator 
PDB                              Protein data bank 
PLS                               Partial least squares 
QSAR                           Quantitative structure–activity relationship 
RECAP                         Retrosynthetic combinatorial analysis procedure 
RMSD                          Root-mean-square deviation 
SAM                             Silent allosteric modulator 
TM                               Trans membrane 
84 
 
 
8.0 BIBLIOGRAPHY 
 
1. Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, et al. Structure of a class C 
GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science. 
2014;344(6179):58-64. 
2. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of 
the human genome. science. 2001;291(5507):1304-51. 
3. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nature 
reviews Drug discovery. 2006;5(12):993-6. 
4. Feng Z, Hu G, Ma S, Xie X-Q. Computational Advances for the Development of 
Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors. The AAPS journal. 
2015;17(5):1080-95. 
5. Wenthur CJ, Gentry PR, Mathews TP, Lindsley CW. Drugs for allosteric sites on 
receptors. Annual review of pharmacology and toxicology. 2014;54:165. 
6. Wellendorph P, Bräuner‐Osborne H. Molecular basis for amino acid sensing by family 
CG‐protein‐coupled receptors. British journal of pharmacology. 2009;156(6):869-84. 
7. Lane JR, Abdul-Ridha A, Canals M. Regulation of G protein-coupled receptors by 
allosteric ligands. ACS chemical neuroscience. 2013;4(4):527-34. 
8. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, 
et al. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and 
opportunities for central nervous system drug discovery. Journal of medicinal chemistry. 
2012;55(4):1445-64. 
85 
 
9. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug 
discovery. Nature Reviews Drug Discovery. 2002;1(3):198-210. 
10. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel 
approach for the treatment of CNS disorders. Nature reviews Drug discovery. 2009;8(1):41-54. 
11. Bridges TM, Lindsley CW. G-protein-coupled receptors: from classical modes of 
modulation to allosteric mechanisms. ACS chemical biology. 2008;3(9):530-41. 
12. Digby GJ, Conn PJ, Lindsley CW. Orthosteric-and allosteric-induced ligand-directed 
trafficking at GPCRs. Current opinion in drug discovery & development. 2010;13(5):587. 
13. Fang Z, Grütter C, Rauh D. Strategies for the selective regulation of kinases with 
allosteric modulators: exploiting exclusive structural features. ACS chemical biology. 
2012;8(1):58-70. 
14. Möhler H, Fritschy J, Rudolph U. A new benzodiazepine pharmacology. Journal of 
Pharmacology and Experimental Therapeutics. 2002;300(1):2-8. 
15. Pin J-P, Galvez T, Prézeau L. Evolution, structure, and activation mechanism of family 
3/C G-protein-coupled receptors. Pharmacology & therapeutics. 2003;98(3):325-54. 
16. Doré AS, Okrasa K, Patel JC, Serrano-Vega M, Bennett K, Cooke RM, et al. Structure of 
class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature. 
2014;511(7511):557-62. 
17. Li G, Jørgensen M, Campbell BM. Metabotropic glutamate receptor 5-negative allosteric 
modulators for the treatment of psychiatric and neurological disorders (2009-July 2013). 
Pharmaceutical patent analyst. 2013;2(6):767-802. 
86 
 
18. Levenga J, Hayashi S, de Vrij FM, Koekkoek SK, van der Linde HC, Nieuwenhuizen I, 
et al. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiology of 
disease. 2011;42(3):311-7. 
19. Ritzén A, Sindet R, Hentzer M, Svendsen N, Brodbeck RM, Bundgaard C. Discovery of 
a potent and brain penetrant mGluR5 positive allosteric modulator. Bioorganic & medicinal 
chemistry letters. 2009;19(12):3275-8. 
20. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and 
lessons learned. Nature reviews Drug discovery. 2007;6(3):211-9. 
21. Joseph-McCarthy D, Campbell AJ, Kern G, Moustakas D. Fragment-based lead 
discovery and design. Journal of chemical information and modeling. 2014;54(3):693-704. 
22. Allen KN, Bellamacina CR, Ding X, Jeffery CJ, Mattos C, Petsko GA, et al. An 
experimental approach to mapping the binding surfaces of crystalline proteins. The Journal of 
Physical Chemistry. 1996;100(7):2605-11. 
23. Chessari G, Woodhead AJ. From fragment to clinical candidate—a historical perspective. 
Drug discovery today. 2009;14(13):668-75. 
24. de Kloe GE, Bailey D, Leurs R, de Esch IJ. Transforming fragments into candidates: 
small becomes big in medicinal chemistry. Drug discovery today. 2009;14(13):630-46. 
25. Jencks WP. On the attribution and additivity of binding energies. Proceedings of the 
National Academy of Sciences. 1981;78(7):4046-50. 
26. Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nature 
Reviews Drug Discovery. 2005;4(8):649-63. 
87 
 
27. Howard N, Abell C, Blakemore W, Chessari G, Congreve M, Howard S, et al. 
Application of fragment screening and fragment linking to the discovery of novel thrombin 
inhibitors. Journal of medicinal chemistry. 2006;49(4):1346-55. 
28. Edwards PD, Albert JS, Sylvester M, Aharony D, Andisik D, Callaghan O, et al. 
Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-
Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency §. 
Journal of medicinal chemistry. 2007;50(24):5912-25. 
29. Sun C, Petros AM, Hajduk PJ. Fragment-based lead discovery: challenges and 
opportunities. Journal of computer-aided molecular design. 2011;25(7):607-10. 
30. Loving K, Alberts I, Sherman W. Computational approaches for fragment-based and de 
novo design. Current topics in medicinal chemistry. 2010;10(1):14-32. 
31. Schuffenhauer A, Ruedisser S, Marzinzik A, Jahnke W, Selzer P, Jacoby E. Library 
design for fragment based screening. Current topics in medicinal chemistry. 2005;5(8):751-62. 
32. Siegal G, Eiso A, Schultz J. Integration of fragment screening and library design. Drug 
discovery today. 2007;12(23):1032-9. 
33. Lepre C. Fragment-based drug discovery using the SHAPES method. Expert opinion on 
drug discovery. 2007;2(12):1555-66. 
34. Fjellström O, Akkaya S, Beisel H-G, Eriksson P-O, Erixon K, Gustafsson D, et al. 
Creating novel activated factor xi inhibitors through fragment based lead generation and 
structure aided drug design. PloS one. 2015;10(1):e0113705. 
35. Ni S, Yuan Y, Huang J, Mao X, Lv M, Zhu J, et al. Discovering potent small molecule 
inhibitors of cyclophilin A using de novo drug design approach. Journal of medicinal chemistry. 
2009;52(17):5295-8. 
88 
 
36. Huang Z, Mou L, Shen Q, Lu S, Li C, Liu X, et al. ASD v2. 0: updated content and novel 
features focusing on allosteric regulation. Nucleic acids research. 2014;42(D1):D510-D6. 
37. Christopher JA, Aves SJ, Bennett KA, Doré AS, Errey JC, Jazayeri A, et al. Fragment 
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